# Every FDA drug approval in 2025: Number of new treatments dipped during agency upheaval

**Source:** Endpoints News
**URL:** https://e.endpointsnews.com/t/t-l-wxihdk-jykykhhuld-d/
**Date:** 2026-01-09

---

CHANNELS WEBINARS SIGNAL MORE

LOG IN

January 8, 2026 11:00 AM ESTUpdated 11:44 AM FDA+

Every FDA drug ap­proval in 2025: Num­ber of new treat­ments dipped dur­ing agency up­heaval

ENDPOINTS

It was a chaot­ic year at the Food and Drug Ad­min­is­tra­tion. Thou­sands of staff left the agency. Lead­er­ship was un­sta­ble. Rou­tine drug …

MORE LIKE THIS

FDA re­jects Van­da’s jet lag drug fol­low­ing years­long dis­pute and 'long-shot' re­view

January 8, 2026

Dereg­u­lat­ing the rapid­ly evolv­ing dig­i­tal health in­dus­try

January 8, 2026

FDA in 2025 holds fewest num­ber of ad­comms since the pan­dem­ic

January 7, 2026

Sanofi calls re­jec­tion of po­ten­tial MS block­buster 'un­ex­pect­ed,' says it saw 'e­volv­ing' FDA per­spec­tives

2025's huge FDA staff cuts most­ly did­n't im­pact new drug re­view time­lines, analy­sis finds

Servi­er launch­es VC unit fo­cused on Eu­ro­pean biotech star­tups

Obe­si­ty biotech Alveus gains $160M for push in­to Mar­i­Tide's back­yard — and amylins

Up­dat­ed: No­vo Nordisk launch­es We­govy pill for as lit­tle as $25 a month for in­sured pa­tients

Lil­ly to pay $1.2B for Ven­tyx and its NL­RP3 drugs

Bioscience & Technology Business Center

The University of Kansas

Lawrence, Kansas

latest

All News

Special

In Focus

channels

Bioregnum

Biotech Voices

Cell/Gene Tx

China

Coronavirus

Deals

Diagnostics

Discovery

FDA+

Financing

Health Tech

Letters to the Editor

Manufacturing

Marketing

Nikkei Biotechnology

Opinion

Outsourcing

Peer Review

People

Pharma

Startups

Weekly

more

Work at Endpoints

Letter to Editors

Editorial Standards

IPO Tracker

Events

Webinars

Sponsored Posts

Advertise

Endpoints Merch

About Us

Help

work in biotech

Endpoints Careers

© Endpoints News 2026

---

#news #endpoints-news
